These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12523918)

  • 41. First case report of familial hypercholesterolemia in an Omani family due to novel mutation in the low-density lipoprotein receptor gene.
    Al-Hinai AT; Al-Abri A; Al-Dhuhli H; Al-Waili K; Al-Sabti H; Al-Yaarubi S; Al-Hashmi K; Banerjee Y; Al-Zakwani I; Al-Rasadi K
    Angiology; 2013 May; 64(4):287-92. PubMed ID: 23162007
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group.
    Lambert M; Lupien PJ; Gagné C; Lévy E; Blaichman S; Langlois S; Hayden M; Rose V; Clarke JT; Wolfe BM; Clarson C; Parsons H; Stephure DK; Potvin D; Lambert J
    Pediatrics; 1996 May; 97(5):619-28. PubMed ID: 8628597
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication.
    Benn M; Watts GF; Tybjaerg-Hansen A; Nordestgaard BG
    J Clin Endocrinol Metab; 2012 Nov; 97(11):3956-64. PubMed ID: 22893714
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Self-reported adherence to cholesterol-lowering medication in patients with familial hypercholesterolaemia: the role of illness perceptions.
    Senior V; Marteau TM; Weinman J;
    Cardiovasc Drugs Ther; 2004 Nov; 18(6):475-81. PubMed ID: 15770435
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cascade screening for familial hypercholesterolemia: Practical consequences.
    Louter L; Defesche J; Roeters van Lennep J
    Atheroscler Suppl; 2017 Nov; 30():77-85. PubMed ID: 29096865
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.
    Raal FJ; Hovingh GK; Blom D; Santos RD; Harada-Shiba M; Bruckert E; Couture P; Soran H; Watts GF; Kurtz C; Honarpour N; Tang L; Kasichayanula S; Wasserman SM; Stein EA
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):280-290. PubMed ID: 28215937
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia.
    Goldammer A; Wiltschnig S; Heinz G; Jansen M; Stulnig T; Hörl WH; Derfler K
    Metabolism; 2002 Aug; 51(8):976-80. PubMed ID: 12145769
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
    Bruckert E; De Gennes JL; Malbecq W; Baigts F
    Clin Cardiol; 1995 Nov; 18(11):621-9. PubMed ID: 8590530
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of fluvastatin on lipid profile and apolipoproteins in Chinese patients with hypercholesterolemia.
    Tomlinson B; Mak TW; Tsui JY; Woo J; Shek CC; Critchley JA; Masarei JR
    Am J Cardiol; 1995 Jul; 76(2):136A-139A. PubMed ID: 7604789
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ezetimibe treatment of pediatric patients with hypercholesterolemia.
    Clauss S; Wai KM; Kavey RE; Kuehl K
    J Pediatr; 2009 Jun; 154(6):869-72. PubMed ID: 19230898
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia.
    Rubba P; Gentile M; Marotta G; Iannuzzi A; Sodano M; De Simone B; Jossa F; Iannuzzo G; Giacobbe C; Di Taranto MD; Fortunato G
    Eur J Prev Cardiol; 2017 Jul; 24(10):1051-1059. PubMed ID: 28353356
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term maintenance of therapeutic response to lovastatin in patients with familial and non-familial hypercholesterolemia: a 3-year follow-up.
    Ojala JP; Helve E; Karjalainen K; Tarkkanen A; Tikkanen MJ
    Atherosclerosis; 1990 May; 82(1-2):85-95. PubMed ID: 2360923
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-Term Cardiovascular Risk in Heterozygous Familial Hypercholesterolemia Relatives Identified by Cascade Screening.
    Kjærgaard KA; Christiansen MK; Schmidt M; Olsen MS; Jensen HK
    J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28652386
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART).
    Matsuzaki M; Hiramori K; Imaizumi T; Kitabatake A; Hishida H; Nomura M; Fujii T; Sakuma I; Fukami K; Honda T; Ogawa H; Yamagishi M
    J Am Coll Cardiol; 2002 Jul; 40(2):220-7. PubMed ID: 12106923
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades.
    Elis A; Zhou R; Stein EA
    Am J Cardiol; 2011 Jul; 108(2):223-6. PubMed ID: 21545982
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Low-density lipoprotein apheresis as long-term treatment for children with homozygous familial hypercholesterolemia.
    Zwiener RJ; Uauy R; Petruska ML; Huet BA
    J Pediatr; 1995 May; 126(5 Pt 1):728-35. PubMed ID: 7751996
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term treatment of severe familial hypercholesterolemia in children: effect of sitosterol and bezafibrate.
    Becker M; Staab D; Von Bergman K
    Pediatrics; 1992 Jan; 89(1):138-42. PubMed ID: 1727999
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evolocumab and lipoprotein apheresis combination therapy may have synergic effects to reduce low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemia: A case report.
    Zenti MG; Stefanutti C; Sanga V; Altomari A; Fabris A; Dauriz M; Bonora E
    J Clin Apher; 2018 Aug; 33(4):546-550. PubMed ID: 29638018
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.
    Stefanutti C; Blom DJ; Averna MR; Meagher EA; Theron Hd; Marais AD; Hegele RA; Sirtori CR; Shah PK; Gaudet D; Vigna GB; Sachais BS; Di Giacomo S; du Plessis AM; Bloedon LT; Balser J; Rader DJ; Cuchel M;
    Atherosclerosis; 2015 Jun; 240(2):408-14. PubMed ID: 25897792
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Changes in ultracentrifugally separated plasma lipoprotein subfractions in patients with polygenic hypercholesterolemia, familial combined hyperlipoproteinemia, and familial hypercholesterolemia after treatment with atorvastatin.
    Homma K; Homma Y; Yoshida T; Ozawa H; Shiina Y; Wakino S; Hayashi K; Itoh H; Hori S
    J Clin Lipidol; 2015; 9(2):210-6. PubMed ID: 25911077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.